Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol

Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol

Introduction Gastroenteropancreatic neuroendocrine tumours (GEP NET) are malignant neoplasms that impact survival. Somatostatin analogues (SSA) are used for treating hormonal symptoms caused by GEP NET and have antiproliferative effects. They are used as first-line therapy in patients with advanced...

Full description

Saved in:
Bibliographic Details
Main Authors: Suzanne Polinder, Ivan Borbath, Marc Peeters, Philippe Beutels, Elke Smits, Iris Verhaegen, Ella Roelant, Wouter Dercksen, Stella Heemskerk, Siddharth Chhajlani, Jelka Kuiper, Christophe M Deroose, Isolde Van der Massen, Annemiek Walenkamp, Wouter W de Herder, Johannes Hofland, Timon Vandamme
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/7/e099996.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items